Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Novelion Therapeutics Inc. (NASDAQ: NVLN).

Full DD Report for NVLN

You must become a subscriber to view this report.


Recent News from (NASDAQ: NVLN)

Novelion therapeutics announces next phase of operational improvements
Novelion Therapeutics (NASDAQ: NVLN ) announces the next phase of operational improvements, following the January announcement of its initial cost reduction initiative. More news on: Novelion Therapeutics, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 23 2018 09:00
Novelion Therapeutics Announces Next Phase of Operational Improvements
VANCOUVER, British Columbia, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the next phase of ope...
Source: GlobeNewswire
Date: August, 23 2018 07:43
Novelion Therapeutics beats by $0.20, misses on revenue
Novelion Therapeutics (NASDAQ: NVLN ): Q2 EPS of -$0.59 beats by $0.20 . More news on: Novelion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 07 2018 08:59
Novelion Therapeutics Reports Second Quarter 2018 Financial Results
VANCOUVER, British Columbia, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”), to...
Source: GlobeNewswire
Date: August, 07 2018 08:30
Your Daily Pharma Scoop: Puma Progresses, Kala In Phase 3, Teva Fails
Stocks in the News: PBYI, KALA Puma Bio's Nerlynx marketing application in Canada under review Puma Biotechnology's ( PBYI ) New Drug Submission (‘NDS) for NERLYNX ( neratinib ) for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer is...
Source: SeekingAlpha
Date: August, 02 2018 06:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-144.004.024.043.9717,567

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1419,33941,68746.3910Short
2018-12-1322,31978,75428.3401Cover
2018-12-122,60969,3683.7611Cover
2018-12-1126,554122,41521.6918Cover
2018-12-1050,840110,07946.1850Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NVLN.


About Novelion Therapeutics Inc. (NASDAQ: NVLN)

Logo for Novelion Therapeutics Inc. (NASDAQ: NVLN)

Not available

 

Contact Information

 

 

Current Management

  • Julia Levy / President, CEO

Current Share Structure

  • Market Cap: $82,855,194 - 05/18/2018
  • Issue and Outstanding: 18,703,204 - 03/12/2018

 


Recent Filings from (NASDAQ: NVLN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 23 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: August, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 07 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 07 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: July, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 19 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: July, 16 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: July, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 03 2018

 

 


Daily Technical Chart for (NASDAQ: NVLN)

Daily Technical Chart for (NASDAQ: NVLN)


Stay tuned for daily updates and more on (NASDAQ: NVLN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NVLN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NVLN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NVLN and does not buy, sell, or trade any shares of NVLN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/